Interleukin-4 in patients with prostate cancer

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Ligand-independent androgen receptor (AR) activation by cytokines is linked to advanced prostate cancer (PCa).
• Interleukin-4 (IL-4) is investigated for its potential role in AR activation and PCa progression.

Purpose of the Study:

• To investigate the effect of elevated Interleukin-4 (IL-4) on androgen receptor (AR) activation in prostate cancer (PCa).
• To determine if IL-4 plays a role in the transition to androgen-independent PCa.

Main Methods:

• LNCaP cells were used for transactivation assays with IL-4 and other cytokines.
• Serum IL-4 concentrations were measured in patients with pre-treatment PCa, hormone-refractory metastatic PCa, benign prostatic hypertrophy, and healthy volunteers.

Main Results:

• Interleukin-4 (IL-4) activated the AR N-terminal domain (NTD) in a ligand-independent manner in LNCaP cells.
• Serum IL-4 levels were significantly higher in patients with hormone-refractory PCa compared to those with pre-treatment PCa.

Conclusions:

• Increased serum IL-4 levels are associated with hormone-refractory prostate cancer (PCa).
• IL-4 enhances prostate-specific antigen (PSA) reporter gene activity via AR NTD activation, suggesting a role in androgen-independent PCa development.